Home
Solutions
Integrated Solutions
Human Challenge Model Advantage

Human Challenge Model Advantage

With more than 25 years experience in delivering Human Challenge Trials, hVIVO is the world leader. With a 50 bed quarantine unit and integrated laboratory facility, industry-leading scientific and regulatory experts hVIVO provides unparalleled delivery

Schedule a Call

Human Challenge Model Advantage

Human challenge models provide a scientifically rigorous and highly controlled method to generate early efficacy signals, enabling sponsors to reach proof‑of‑concept (PoC) up to 3.5× faster than conventional outpatient trials. By using validated challenge strains, controlled exposure, and rapid readouts, human challenge studies de‑risk clinical development and accelerate decision‑making for vaccines, antivirals, monoclonals, and immunomodulators.

Proven to accelerate PoC up to 3.5× faster then field trials
Controlled viral/bacterial exposure enabling precise efficacy measurement
Integrated clinical and laboratory environment for rapid decision‑making
End‑to‑end challenge model design, delivery, and interpretation
Faster execution enabled by agile governance & rapid project start‑up

Integrated Human Challenge Solution

hVIVO Capability

Human challenge trial design & delivery
Comparator strategy
In vitro/in vivo efficacy modelling
Rapid data readouts
Onsite molecular, virology, immunology & bacterial labs
Full quarantine clinical units
Challenge model development

Find out more

Fully Integrated Solution Includes

Challenge trial design & delivery
Comparator strategy
Efficacy in vitro/in vivo
Rapid data readouts
Model development
Quarantine unit – clinical conduct
Integrated specialty laboratories molecular, virology, immunology, bacterial

Why Consider hVIVO

Rapid variant analysis aligned with FDA NGS requirements

Agile challenge model development (<12 months)

Extensive track record

Top line data within one year of start up activity

FAQs

How do challenge studies accelerate PoC?

Controlled exposure enables early human efficacy signals without large outpatient trials.

What products can be evaluated?

Vaccines, antivirals, monoclonals, immunomodulators.

Do you have onsite labs?

Yes – fully integrated molecular, virology, immunology, and bacterial labs.

Can you develop new challenge models?

Yes – we design, refine, and validate bespoke challenge models.

Human Challenge Model Advantage

Human Challenge Model Advantage

hVIVO World Leaders in Human Challenge

Speak to Our Human challenge Experts

Integrated Human Challenge Solution

Why Consider hVIVO

News & Resources

What Small Biotechs Get Wrong About First‑in‑Human Trials

Recruiting for Complex Trials Requires a Different Kind of Engine

Why Modern Site Performance Requires More Than a Site: Lessons from SCRS and the Rise of Integrated Early‑Phase Operations

Why Early Data Management Involvement Is Becoming Essential in the Age of AI

The Early‑Phase Anchor: Why Medical Monitoring Matters Long Before the First Dose

A Stronger Future for UK Clinical Research: Why the New Regulations Align with the Next Era of Early‑Phase Development

Real‑World RSV Maternal Vaccine Data Marks a Turning Point for Infant Protection

A Landmark Moment for Pertussis Vaccine Development — and for the Future of Bacterial Challenge Models

Fast‑Tracking First‑in‑Human: Five Lessons Startups Can’t Afford to Miss

Paper: Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

FAQs

Contact Us